SY-5609
- Generic Name
- SY-5609
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26F3N6OP
- CAS Number
- 2417302-07-7
- Unique Ingredient Identifier
- TW6044C3O6
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04929223
- Locations
- 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Breast CancerPancreatic CancerAdvanced Solid TumorSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT04247126
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath